Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Non-Current Assets (2020 - 2025)

Historic Non-Current Assets for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to $39.5 million.

  • Caribou Biosciences' Non-Current Assets fell 6307.29% to $39.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $218.1 million, marking a year-over-year decrease of 4608.98%. This contributed to the annual value of $93.9 million for FY2024, which is 60.83% up from last year.
  • Per Caribou Biosciences' latest filing, its Non-Current Assets stood at $39.5 million for Q3 2025, which was down 6307.29% from $28.4 million recorded in Q2 2025.
  • Caribou Biosciences' 5-year Non-Current Assets high stood at $113.5 million for Q4 2022, and its period low was $12.9 million during Q3 2021.
  • In the last 5 years, Caribou Biosciences' Non-Current Assets had a median value of $86.5 million in 2022 and averaged $75.0 million.
  • In the last 5 years, Caribou Biosciences' Non-Current Assets surged by 61169.36% in 2022 and then tumbled by 7217.51% in 2025.
  • Caribou Biosciences' Non-Current Assets (Quarter) stood at $51.2 million in 2021, then skyrocketed by 121.87% to $113.5 million in 2022, then fell by 17.75% to $93.4 million in 2023, then grew by 0.61% to $93.9 million in 2024, then plummeted by 57.97% to $39.5 million in 2025.
  • Its Non-Current Assets stands at $39.5 million for Q3 2025, versus $28.4 million for Q2 2025 and $56.3 million for Q1 2025.